ENTRADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ENTRADA THERAPEUTICS, INC. (TRDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 49.31 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 17.94K shares, a 72.37% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 31.37K shares, a 19.11% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 19.07K shares, a 71.84% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 97.21K shares, a 182.32% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 220.00K shares, a 44.91% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 399.33K shares, a 100.11% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 199.56K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 17.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 49.31K shares 10-Q · filed 2026-08-05 | 68.38K shares derived: sum of 3 quarters · filed 2026-08-05 | 165.59K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 31.37K shares 10-Q · filed 2026-05-07 | 50.44K shares derived: sum of 2 quarters · filed 2026-05-07 | 147.65K shares derived: sum of 3 quarters · filed 2026-05-07 | 212.59K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 19.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 116.28K shares derived: sum of 2 quarters · filed 2026-02-26 | 181.21K shares derived: sum of 3 quarters · filed 2026-02-26 | 220.00K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 97.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 162.15K shares derived: sum of 2 quarters · filed 2025-11-06 | 200.93K shares 10-Q · filed 2025-11-06 | 268.64K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 64.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 103.72K shares 10-Q · filed 2025-08-06 | 171.43K shares derived: sum of 3 quarters · filed 2025-08-06 | 205.86K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 38.78K shares 10-Q · filed 2025-05-08 | 106.49K shares derived: sum of 2 quarters · filed 2025-05-08 | 140.92K shares derived: sum of 3 quarters · filed 2025-05-08 | 242.90K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 67.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 102.14K shares derived: sum of 2 quarters · filed 2025-02-27 | 204.11K shares derived: sum of 3 quarters · filed 2025-02-27 | 399.33K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 34.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 136.41K shares derived: sum of 2 quarters · filed 2024-11-05 | 331.63K shares 10-Q · filed 2024-11-05 | 410.89K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 101.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 297.20K shares 10-Q · filed 2024-08-13 | 376.45K shares derived: sum of 3 quarters · filed 2024-08-13 | 424.35K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 195.22K shares 10-Q · filed 2024-05-07 | 274.48K shares derived: sum of 2 quarters · filed 2024-05-07 | 322.38K shares derived: sum of 3 quarters · filed 2024-05-07 | 383.04K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 79.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 127.16K shares derived: sum of 2 quarters · filed 2024-03-13 | 187.82K shares derived: sum of 3 quarters · filed 2024-03-13 | 199.56K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 47.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 108.56K shares derived: sum of 2 quarters · filed 2023-11-07 | 120.30K shares 10-Q · filed 2023-11-07 | |
| 2023-06-30 | 60.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 72.40K shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 11.74K shares 10-Q · filed 2023-05-10 | |||
| 2022-09-30 | 16.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 39.48K shares derived: sum of 2 quarters · filed 2022-11-07 | 63.11K shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 22.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 46.52K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 23.63K shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |